We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GAO Report Critiques FDA’s COVID-19 Vaccine Manufacturing Oversight

GAO Report Critiques FDA’s COVID-19 Vaccine Manufacturing Oversight

November 5, 2021

COVID-19 vaccine makers didn’t undergo preapproval facility inspections before receiving Emergency Use Authorizations (EUAs) from the FDA for their jabs, the Government Accountability Office (GAO) says.

The GAO’s analysis, titled “COVID-19 — Additional Actions Needed to Improve Accountability and Program Effectiveness of Federal Response,” mainly focused on other HHS agencies and government departments and only dealt with the FDA’s role in two appendices.

It notes that the FDA was not required to conduct inspections prior to the emergency authorizations of the Pfizer/BioNTech, Moderna and Johnson & Johnson (J&J) vaccines, all of which occurred during the pandemic, when the agency drastically curtailed inspections.

The GAO’s assessment found that “14 of the 18 establishments that manufacture COVID-19 vaccines had been previously inspected at least once” within the past decade, comprising a total of 90 inspections. For all but one of the 14 facilities, the GAO said, the FDA’s most recent inspection occurred within the past four years.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • MedTrace Receives U.S. Patent for Heart Modeling Method

  • NICE Recommends Epidyolex for Tuberous Sclerosis Complex Seizures

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing